drugset / Trial / NCT07671365

Angiotensin II for Post Cardiac Surgery Vasoplegia (ANGII_V)

NCT07671365 ↗

Phase 4 Not yet recruiting 329 enrolled Methodist Healthcare System of San Antonio
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this study is to conduct a prospective trial implementing a modified version of the Emory Protocol for administering ANG II to patients with post cardiac bypass vasoplegia. The main questions we aim to answer are: 1.) does administration of improve mortality, 2.) does the administration of Ang II using the modified protocol shorten the time needed to reach optimal MAP, 3.) does the administration of Ang II using the modified protocol shorten length of stay in the ICU and hospital? Researchers will compare outcomes from the interventional group to historical controls who did not receive Ang II using the modified protocol.

Timeline

Start
2026-07
Primary completion
2029-07
Completion
2030-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Angiotensin II Peptide 10 ng —
Subject Angiotensin II Peptide 20 ng —
Subject Angiotensin II Peptide 80 ng —